Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy (PRISM)
Phase II Trial Investigating the Safety and Feasibility of Peptide GAM Immunoadsorption in Anti-PLA2R Positive Autoimmune Membranous Nephropathy
Sponsor: Fresenius AG
This NA trial investigates Autoimmune Membranous Nephropathy and is currently completed. Fresenius AG leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting · Phase: PHASE2 → NA
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Apr 2018 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fresenius AG
- Manchester University NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .